A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity

Graeme J. Moyle, Jaime Andrade-Villanueva, Pierre Marie Girard, Andrea Antinori, Patricia Salvato, Johannes R. Bogner, Phillip Hay, Jesús Santos, Ludovic Astier, Miranda Pans, Agnes Balogh, Sophie Biguenet

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Abdominal adiposity in HIV-1 patients initiating antiretroviral therapy may be part of a restoration-to-health phenomenon. Lipoatrophy is associated with long-term thymidine analogue therapy. Individual protease inhibitors (PIs) differ in their effects on lipids and insulin resistance. Methods: A randomized open-label multicentre 96-week trial compared changes in fat distribution in patients with suppressed HIV-1 RNA and abdominal adiposity, who either continued on their current twice-daily ritonavir-boosted PI (PI/r) or switched to once-daily boosted atazanavir (ATV/r). Treatment with two nucleoside reverse transcriptase inhibitors was unchanged. Body composition was assessed by dual-energy x-ray absorptiometry (DEXA) and abdominal computerized tomography (CT) scanning. Results: In total, 201 patients were randomized; 131 switched to ATV/r. Viral suppression (

Original languageEnglish
Pages (from-to)689-700
Number of pages12
JournalAntiviral Therapy
Volume17
Issue number4
DOIs
Publication statusPublished - 2012

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity'. Together they form a unique fingerprint.

Cite this